Methods: We performed a retrospective cross-sectional study of HIV/HCV co-infected patients that were treated between 2014-2017 at Drexel University, Philadelphia, PA. We described patient demographics and overall METAVIR scores of treated patients. Further, we compared the concordance between FibroSure and FibroScan results among patients who had both tests before the start of HCV treatment.
Results: One hundred and thirty-eight HIV/HCV co-infected patients were treated. Most of them (N=134, 97%) achieved sustained virologic response after 12 weeks of treatment. 133 patients underwent FibroSure testing before starting HCV treatment. Of those, 62 (47%) fell in the F0-F2 range and 71 (53%) in the F3-F4 range. Of those 133 patients, 21 also underwent FibroScan. 14(67%) fell in the F0-F2 range, while 7 (33%) fell in the F3-F4 range. Of the 21 patients who both had FibroSure and FibroScan testing, 12 (57%) had concordant results, while 9 (42%) had discrepant results. Of the patients with discrepant results, 8 had higher fibrosis scores (F3-F4) with FibroSure, while only one had a higher fibrosis score (F3-F4) with FibroScan.
Conclusion: In our study, more than half of HIV/HCV co-infected patients had advanced fibrosis score at the time of HCV treatment. When FibroSure and FibroScan scores were compared, close to half of co-infected patients had discordant results, the preponderance of which had higher FibroSure scores. As early initiation of HCV treatment is crucial to co-infected patients, further studies will need to evaluate the clinical significance of the discrepancy between different non-invasive fibrosis testing systems in co-infected patients.
T. Franks, None
T. Scott, None
A. Kesaris, None
E. Chou, None
D. Coppock, None